been found to block the vesicular monoamine transporter 2 (VMAT2). Pharmacokinetics The bioavailability of ketanserin is 50%. The plasma protein binding of ketanserin is 95.0% and it is mainly bound to albumin. The elimination half-life of ketanserin is 10 to 29 hours. Synthesis Either 3-(2-Chloroethyl)quinazoline-2,4(1H,3H)-dione [5081-87-8] (1a), or alternatively 2,3-dihydro-[1,3]oxazolo[2,3-b]quinazolin-5-one [52727-44-3] (1b) can be used as starting material. Attachment of the sidechain to 4-(4-Fluorobenzoyl)piperidine [56346-57-7] (2) completes synthesis synthesis of Ketanserin (3). See also Altanserin Pirenperone Setoperone Pelanserin References 5-HT1D antagonists 5-HT2A antagonists 5-HT2C antagonists 5-HT6 antagonists 5-HT7 antagonists Alpha-1 blockers Alpha-2 blockers Antihypertensive agents D1 antagonists D2 antagonists Fluoroarenes H1 receptor antagonists Imides Janssen Pharmaceutica Ketones Piperidines Quinazolinones VMAT inhibitors